Shijiazhuang Yiling Pharmaceutical002603.SZValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Deeply Undervalued” zone.
As of Oct 19, 2026, Shijiazhuang Yiling Pharmaceutical (002603.SZ) trades at a P/E of 18.30x, P/B of 2.31x, P/S of 3.09x, and a dividend yield of 5.31%.
Longitudinal percentile comparison: P/E sits at the 9th percentile over the trailing 10Y window (vs. 11th percentile over 3Y); P/B sits at the 24th percentile over the trailing 10Y window (vs. 27th percentile over 3Y); P/S sits at the 25th percentile over the trailing 10Y window (vs. 17th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 19th percentile within its industry and the 21st percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 5.31%, ranking at the 99th percentile over the trailing 20Y window.
The P/E and P/B percentiles diverge here, differing by 15.7 points — relying on either metric alone could be misleading. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Shijiazhuang Yiling Pharmaceutical operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: SHE: 002603 · SZSE: 002603 · 002603
Want the full picture on whether Shijiazhuang Yiling Pharmaceutical (002603.SZ) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 18.30 | ||||||
| P/B (MRQ) | 2.31 | ||||||
| P/S (TTM) | 3.09 | ||||||
| Dividend Yield | 5.31% | ||||||
| Buyback + Div Yield | 5.31% |